Breast
Protocol: NSABP FRP FB-5
A Phase II Clinical Trial of Epirubicin Plus Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and Bevacizumab Given as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or Given as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer
PI: Darla Liles, MD
Protocol: ECOG 40101
Cyclophosamide And Doxorubicin (CA) (4 Vs 6 Cycles) Versus Paclitaxel (4 Vs 6 Cycles) As Adjuvant Therapy For Women With Node-Negative Breast Cancer: A 2X2 Factorial Phase III Randomized Study
PI: Darla Liles, MD
Gastric
Protocol: ECOG 80101
Phase III Intergroup Trial of Adjuvant Chemoradiation after Resection of Gastric or Gastroesophageal Adenocarcinoma
PI: Ron Allison, MD
Melanoma
Protocol: ECOG E2603
A Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and BAY 43-9006 versus Carboplatin, Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma
PI: Lillian Burke, MD
Protocol: ECOG E1697
Phase III Randomized Study of Four Weeks High Dose IFN-a2b in Stage T2b No, T3a-b, T4a-b No, and T1-4, N1a, 2a, 3 (microscopic) Melanoma
PI: Walter Quan, MD
